Therapy Areas: Diabetes
Follicum awarded European patent for potential diabetes therapy
13 January 2021 -

Follicum AB (Spotlight:FOLLI), a Swedish developer of drug candidates based on tissue repairing peptides, reported on Wednesday that the European Patent Office (EPO) has approved patent number EP 3,618,845 B1, relating to the company's novel peptides that are being developed to treat diabetes.

This follows the EPO's provisional approval announced in March 2020.

The new patent provides protection for the company's peptides and their use to treat diabetes in Europe until 2038.

Similar patents have previously been approved in the United States. Follicum also has a corresponding patent application under review by authorities in China, Japan, India, Canada, South Korea, Singapore, Israel and Australia.



Related Headlines